First-Ever human trial launches for experimental eye inflammation drug
NCT ID NCT07218770
Summary
This is the first time researchers are testing an experimental drug called REGN7041 in people. The study aims to find out if the drug is safe and tolerable for adults with active, non-infectious inflammation inside the eye (uveitis). Researchers will also measure how much of the drug gets into the blood and eye fluid, and check for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE NONINFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Illinois Retina Associates
RECRUITINGOak Park, Illinois, 60304, United States
Contact Email: •••••@•••••
-
Retina Consultants of Texas
RECRUITINGKaty, Texas, 77494, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Retina Consultants of Texas - Houston
RECRUITINGBellaire, Texas, 77401, United States
Contact Email: •••••@•••••
-
Tennessee Retina
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.